Gyre Therapeutics (GYRE) Current Leases (2019 - 2026)
Gyre Therapeutics (GYRE) reported Current Leases of $751000.0 for Q1 2026, down 6.71% year-over-year from $805000.0 in Q1 2025, and up 18.08% on a QoQ basis from $636000.0 in Q4 2025.
Gyre Therapeutics (GYRE) has 8 years of Current Leases data on file, last reported at $751000.0 in Q1 2026.
- Quarterly Current Leases fell 6.71% year-over-year to $751000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $751000.0 (down 6.71% YoY) and the FY2025 annual result came in at $636000.0, down 10.8% from the prior year.
- Current Leases improved to $751000.0 in Q1 2026 per GYRE's latest filing, from $636000.0 in the prior quarter.
- Across five years, Current Leases topped out at $1.9 million in Q1 2022 and bottomed at $100000.0 in Q1 2024.
- The 5-year median for Current Leases is $647500.0 (2024), against an average of $715214.3.
- The widest annual swing landed in 2022, when Current Leases slumped 79.34%; it then surged 705.0% in 2025.
- Tracing GYRE's Current Leases over 5 years: stood at $492000.0 in 2022, then plunged by 57.32% to $210000.0 in 2023, then soared by 239.52% to $713000.0 in 2024, then decreased by 10.8% to $636000.0 in 2025, then grew by 18.08% to $751000.0 in 2026.
- Per Business Quant, the three latest GYRE Current Leases figures stand at $751000.0 (Q1 2026), $636000.0 (Q4 2025), and $626000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 83,991.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 7.40 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 720.00 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 45.66 Mn |
| 10 | Gyre Therapeutics | 532.38 Mn | 518.25 Mn | 8.38 Mn | 751,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 751,000.00 |
| Dec 31, 2025 | 636,000.00 |
| Sep 30, 2025 | 626,000.00 |
| Jun 30, 2025 | 622,000.00 |
| Mar 31, 2025 | 805,000.00 |
| Dec 31, 2024 | 713,000.00 |
| Sep 30, 2024 | 694,000.00 |
| Jun 30, 2024 | 659,000.00 |
| Mar 31, 2024 | 100,000.00 |
| Dec 31, 2023 | 210,000.00 |
| Dec 31, 2022 | 492,000.00 |
| Sep 30, 2022 | 381,000.00 |
| Jun 30, 2022 | 1.42 Mn |
| Mar 31, 2022 | 1.91 Mn |
| Dec 31, 2021 | 1.98 Mn |
| Sep 30, 2021 | 1.84 Mn |
| Jun 30, 2021 | 1.81 Mn |
| Mar 31, 2021 | 678,000.00 |
| Dec 31, 2020 | 663,000.00 |
| Sep 30, 2020 | 519,000.00 |
| Jun 30, 2020 | 507,000.00 |
| Mar 31, 2020 | 495,000.00 |
| Dec 31, 2019 | 483,000.00 |
| Sep 30, 2019 | 472,000.00 |
| Jun 30, 2019 | 461,000.00 |
| Mar 31, 2019 | 450,000.00 |